Nivolumab plus ipilimumab for potentially resectable hepatocellular carcinoma: Long-term efficacy and biomarker exploration.
Lin YJ, Ou DL, Su YY, Hsu CL, Hsiao CF, Ko BS, Chen SC, Wang HW, Wang JH, Wu YM, Jeng YM, Lee WC, Chou SC, Chen TW, Chiu CF, Lin JS, Hsieh CH, Lee CC, Shan YS, Cheng AL, Chen LT, Hsu C.
Lin YJ, et al. Among authors: lin js.
J Hepatol. 2025 Sep 17:S0168-8278(25)02471-7. doi: 10.1016/j.jhep.2025.08.035. Online ahead of print.
J Hepatol. 2025.
PMID: 40972843